New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
08:05 EDTTSRXTrius Therapeutics completes enrollment of second Phase 3 trial of Tedizolid
Trius Therapeutics announced that it has reached its enrollment objective of 658 patients in the last of its two Phase 3 clinical trials of tedizolid phosphate, or TR-701, for the treatment of acute bacterial skin and skin structure infections. The pivotal Phase 3 trial, designated ESTABLISH 2, examines the efficacy and safety of a six-day course of tedizolid administered once a day versus a 10-day course of linezolid, or Zyvox, administered twice a day in patients recruited across sites in North and South America, Europe, Australia, New Zealand and South Africa. For both tedizolid phosphate and linezolid, drug was initially administered as an intravenous infusion with the option to switch to oral therapy after the initial day of therapy.
News For TSRX From The Last 14 Days
Check below for free stories on TSRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for TSRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use